Form 8-K · Current report
West Pharmaceutical Services 8-K, filed Jul 23, 2026
- Filed
- CIK
- 0000105770
- Accession no.
- 0000105770-26-000097
Summary
West Pharmaceutical Services reported strong second-quarter 2026 financial results, achieving net sales of $872.3 million and diluted earnings per share of $2.15. The company also increased its financial guidance for both the full year and the third quarter of 2026.
Key points
- Second-quarter net sales reached $872.3 million, representing a 12.7% organic growth and a 13.8% increase year-over-year.
- Management announced a third-quarter 2026 dividend of $0.22 per share from its Board of Directors.
- The company raised its full-year 2026 net sales guidance to a range of $3.345 billion to $3.380 billion and its adjusted-diluted EPS guidance to $8.85 to $9.05.
- West Pharmaceutical Services repurchased 1.8 million shares during the first six months of 2026 for $454.3 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 23, 2026, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its second-quarter 2026 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.